Drug Profile
Research programme: neuroprotectants - Cenomed BioSciences
Alternative Names: Biodefense therapeutics - Cenomed BioSciences LLC; CB-2,501; Chemical defense programme - Cenomed BioSciences LLC; CM-2,501Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cenomed BioSciences LLC
- Class Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Cholinergic receptor modulators; Imidazoline receptor agonists; Serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders(Prevention) in USA
- 30 Jun 2010 Celgene Corporation to acquire Abraxis BioScience
- 25 Sep 2007 Cenomed BioSciences LLC establishes CRADA with the United States Army Medical Research Institute of Chemical Defense for the development of CM 2501 and related compounds as biodefense agents